Pharmaceutical GW Pharmaceuticals today announced positive results of the second randomized, double-blind, placebo-controlled Phase III clinical trial of its investigational medicine Epidiolex (cannabidiol or CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. 26 September 2016